Monitoring antiplatelet therapy with point-of-care platelet function assays: A review of the evidence

Future Cardiology

Volumn 4, Issue 1, 2008, Pages 33-55

  van Werkum, Jochem W ^a   Hackeng, Christian M ^a   Smit, Jaap Jan J ^b   van't Hof, Arnoud W J ^b   Verheugt, Freek W A ^c   ten Berg, Jurrien M ^a  

^a St Antonius Center for Platelet Function Research   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspirin; Clopidogrel; Gp IIb IIIa therapy; Monitoring antiplatelet therapy; Point of care

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; PRASUGREL; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANALYTICAL EQUIPMENT; ANTICOAGULATION; ASPIRIN RESISTANCE; BLEEDING; BLOOD CLOTTING PARAMETERS; BLOOD EXAMINATION; CELL ASSAY; CENTRIFUGATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG RESISTANCE; DRUG RESPONSE; DRUG SCREENING; GOLD STANDARD; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTERMETHOD COMPARISON; LIGHT TRANSMITTANCE AGGREGOMETRY; LOADING DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; POINT OF CARE TESTING; PRIORITY JOURNAL; RECEPTOR BLOCKING; REPRODUCIBILITY; REVIEW; STABLE ANGINA PECTORIS; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOELASTOGRAPHY; THROMBOGENESIS; TURBIDIMETRY;

EID: 38049158234     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.4.1.33     Document Type: Review

References (143)

1. Azuma H, Ishikawa M, Sekizaki S: Endothelium-dependent inhibition of platelet aggregation. Br. J. Pharmacol. 88(2), 411-415 (1986).
2. Radomski MW, Palmer RM, Moncada S: the anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 92(3), 639-646 (1987).
3. Michelson AD, Benoit SE, Furman MI et al.: Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am. J. Physiol. 270(5 Pt 2), H1640-H1648 (1996).
4. Sugimoto M, Tsuji S, Kuwahara M et al.: Shear-dependent functions of the interaction between soluble von Willebrand factor and platelet glycoprotein Ib in mural thrombus formation on a collagen surface. Int. J. Hematol. 69(1), 48-53 (1999).
5. Wu YP, Vink T, Schiphorst M et al. Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction. Arterioscler. Thromb. Vasc. Biol. 20(6), 1661-1667 (2000).
6. Nurden AT, Nurden P: A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. Baillieres Clin. Haematol. 6(3), 653-690 (1993).
7. Shattil SJ: Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104, 1606-1615 (2006).
8. Kato K, Kanaji T, Russell S et al.: The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 102, 1701-1707 (2003).
9. Reed G: Platelet secretory mechanisms. Semin. Thromb. Haemost. 30, 441-450 (2004).
10. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). CAPRIE Steering Committee. Lancet 348(9038), 1329-1339 (1996).
11. Mehta SR, Yusuf S, Peters RJ et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527-533 (2001).
12. Steinhubl SR, Berger PB, Mann JT 3rd et al..: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411-2420 (2002).
13. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001).
14. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M: Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89(5), 783-787 (2003).
15. Matetzky S, Shenkman B, Guetta V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109(25), 3171-3175 (2004).
16. Cuisset T, Frere C, Quilici J et al.: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb. Haemost. 4(3), 542-549 (2006).
17. Gurbel PA, Bliden KP, Guyer K et al.: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol. 46(10), 1820-1826 (2005).
18. Hochholzer W, Trenk D, Fischer B et al.: Impact of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48 (9), 1742-1750 (2006).
19. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor In high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med. 330(14), 956-961 (1994).
20. Boersma E, Harrington RA, Moliterno DJ, White H, Simoons ML: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet 360(9329), 342-343 (2002).
21. Boersma E, Harrington RA, Moliterno DJ et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359(9302), 189-198 (2002).
22. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML: Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Cirulation 100(20), 2045-2048 (1999).
23. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N. Engl. J. Med. 336(24), 1689-1696 (1997).
24. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 352(9122), 87-92 (1998).
25. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 96(5), 1445-1453 (1997).
26. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. 338(21), 1488-1497 (1998).
27. Montalescot G, Barragan P, Wittenberg O et al.: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. 344(25), 1895-1903 (2001).
28. Van't Hof AW, Ernst N, de Boer MJ et al.: Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur. Heart J. 25(10), 837-846 (2004).
29. Batchelor WB, Tolleson TR, Huang Y et al.: Randomized Comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet Aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 106(12), 1470-1476 (2002).
30. Steinhubl SR, Kottke-Marchant K, Moliterno DJ et al.: Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 100(19), 1977-1982 (1999).
31. Weiss EJ, Bray PF, Tayback M et al.: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N. Engl. J. Med. 334(17), 1090-1094 (1996).
32. Holmes MB, Kabbani SS, Terrien CM, Watkins MW, Sobel BE, Schneider DJ: Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab. Coron. Artery Dis. 12(3), 245-253 (2001).
33. Holmes MB, Sobel BE, Schneider DJ: Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am. J. Cardiol. 84(2), 203-207 (1999).
34. Tcheng JE, Ellis SG, George BS et al.: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90(4), 1757-1764 (1994).
35. Hobbach HF, Schuster P: Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Z. Kardiol. 92(3), 213-218 (2003).
36. Simon DI, Liu CB, Ganz P et al.: A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter. Cardiovasc. Interv. 52(4), 425-432 (2001).
37. Barrett JS, Murphy G, Peerlinck K et al.: Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin. Pbarmacol. Ther. 56(4), 377-388 (1994).
38. Harrington RA, Kleiman NS, Kottke-Marchant K et al.: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol. 76(17), 1222-1227 (1995).
39. Van Cott EM, Fletcher SR, Kratz A: Effects of the blood-collection tube material and long-term storage on platelet activation parameters on the ADVIA 120/2120 hematology system. Lab. Hematol. 11(1), 71-75 (2005).
40. Van Cott EM, Lewandrowski KB, Patel S et al.: Comparison of glass K3EDTA versus plastic K2EDTA blood-drawing tubes for complete blood counts, reticulocyte counts, and white blood cell differentials. Lab. Hematol. 9(1), 10-14 (2003).
41. Mani H, Kirchmayr K, Klaffling C et al.: Influence of blood collection techniques on platelet function. Platelets 15(5), 315-318 (2004).
42. Mani H, Luxembourg B, Klaffling C, Erbe M, Lindhoff-Last E: Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J. Clin. Pathol. 58(7), 747-750 (2005).
43. Breddin HK, Ziemen H, Bauer O et al.: Time and temperature dependent changes of ADP - and collagen-induced and "spontaneous" aggregation. Thromb. Res. 19(4-5), 621-638 (1980).
44. Patel P, Gonzales R, Dokainish H, Lakkis N: Impact of adenosine diphosphate and calcium chelation on platelet aggregation testing in patients receiving clopidogrel therapy. J Am. Coll. Cardiol. 47(2), 464-465 (2006).
45. 2+ on GP IIb-IIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 96(5), 1488-1494 (1997).
46. 2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb. Haemost. 85(3), 539-543 (2001).
47. Labarthe B, Theroux P, Angioi M, Ghitescu M: Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J. Am. Coll. Cardiol. 46(4), 638-645 (2005).
48. 1 antagonists but not aspirin. Thromb. Res. 115(4), 301-307 (2005).
49. Mascelli MA, Kleiman NS, Marciniak SJ Jr, Damaraju L, Weisman HF, Jordan RE: Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/ IIIa antagonist abciximab. Am. Heart J. 139(4), 696-703 (2000).
50. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A: Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93(2), 229-237 (1996).
51. Gurbel PA, Samara WM, Bliden KP: Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 15(2), 95-99 (2004).
52. Soffer D, Moussa I, Harjai KJ et al.: Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter. Catdiovasc. Interv. 59(1), 21-25 (2003).
53. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 45(9), 1392-1396 (2005).
54. O'Brien JR, Shoobridge SM, Finch WJ: Comparison of the effect of heparin and citrate on platelet aggregation. J. Clin. Pathol. 22, 28-31 (1969).
55. Warlow C, Ogston D, Douglas AS: The relationship between platelet aggregation and the time interval after venipuncture. Thromb. Diath. Haemorrh. 31, 133-141 (1974).
56. Hayward CP, Eikelboom J: Platelet function testing: quality assurance. Semin. Thromb. Hemost. 33(3), 273-282 (2007).
57. Born GV, Dearnley R, Foulks JG, Sharp DE: Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors. J. Physiol 280, 193-212 (1978).
58. Born GV: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194, 927-929 (1962).
59. Sixma JJ: Methods for platelet aggregation. In: Platelet Function and Thrombosis, Vol. 34. Mannucci PM GS (Ed.). Plenum Press, NY, USA, 79 (1972).
60. Riess H, Braun G, Brehm G, Hiller E: Critical evaluation of platelet aggregation in whole human blood. Am. J. Clin. Pathol. 85(1), 50-56 (1986).
61. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS: Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 286(10), 1187-1194 (2001).
62. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Card. 41(6), 961-965 (2003).
63. Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruiany VL: Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur. J. Pharmacol. 462(1-3), 139-143 (2003).
64. Tantry US, Bliden KP, Gurbel PA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J. Am. Coll. Cardiol. 46(9), 1705-1709 (2005).
65. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM: Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36(5), 1001-1005 (2005).
66. Serebruany VL, Malinin AI, Sane DC: Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage? Am. J. Hematol. 72(4), 280-281 (2003).
67. Lennon MJ, Gibbs NM, Weightman WM, McGuire D, Michalopoulos N: A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J. Cardiothorac. Vasc. Anesth. 18(2), 136-140 (2004).
68. Gum PA, Kottke-Marchant K, Poggio ED et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 88(3), 230-235 (2001).
69. Gawaz M, Ruf A, Pogatsa-Murray G et al.: Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb. Haemost. 83(6), 915-922 (2000).
70. Geisler T, Langer H, Wydymus M et al.: Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur. Heart J. 27(20), 2420-2425 (2006).
71. Buonamici P, Marcucci R, Migliorini A et al.: Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49(24), 2312-2317 (2007).
72. Carville DG, Schleckser PA, Guyer KE, Corsello M, Walsh MM: Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J. Extra Corpor. Technol. 30(4), 171-177 (1998).
73. Storey RF, Wilcox RG, Heptinstall S: Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation 98(16), 1616-1621 (1998).
74. Karha J, Bhatt DL, Kottke-Marchant K: Use of Plateletworks™ vs. arachidonic acid aggregation to detect aspirin effect in healthy volunteers. J. Thromb. Haemost. 3(Suppl. 1), 1-8 (2005).
75. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC: Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J. Lab. Clin. Med. 145(6), 309-315 (2005).
76. Lau WC, Waskell LA, Watkins PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107(1), 32-37 (2003).
77. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC: Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. Cardiol. 93(4), 456-458 (2004).
78. Lakkis NM, George S, Thomas E, Ali M, Guyer K, Carville D: Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors. Catheter. Cardiovasc. Interv. 53(3), 346-351 (2001).
79. White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK: The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists. J. Thromb. Thrombolysis. 18(3), 163-169 (2004).
80. Ray MJ, Walters DL, Bett N, Cameron J, Wood P, Aroney C: Point-of-care testing shows clinically relevant variation in the degree of Inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention. Catheter. Cardiovasc. Interv. 62(2), 150-154 (2004).
81. Smit JJ, Ernst NM, Slingerland RJ et al.: Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome. Am. Heart J. 151(5), 1109-1114 (2006).
82. Favaloro EJ: Clinical application of the PFA-100. Curr Opin. Hematol. 9(5), 407-415 (2002).
83. Mammen EF, Comp PC, Gosselin R et al.: PFA-100 system: a new method for assessment of platelet dysfunction. Semin.Thromb. Hemost. 24(2), 195-202 (1998).
84. Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ: The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin. Appl. Thromb. Hemost. 5(2), 122-130 (1999).
85. Wataia, C, Golanski J, Rozalski M et al.: Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100? Thromb. Res. 109(5-6), 299-306 (2003).
86. Frossard M, Fuchs I, Leitner JM et al.: Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110(11), 1392-1397 (2004).
87. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B: Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J. Thromb. Haemost. (2006).
88. Chakroun T, Gerotziafas G, Robert F et al.: In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br. J. Haematol. 124(1), 80-85 (2004).
89. Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert UT, Hellstern P: Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br. J. Haematol. 130(5), 759-767 (2005).
90. Golanski J, Pluta J, Baranlak J, Watala C: Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists - in vitro experience. Clin. Chem. Lab Med. 42(1), 25-29 (2004).
91. Hezard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P: PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb. Res. 108(1), 43-47 (2002).
92. Coleman JL, Wang JC, Son DI: Determination of Individual response to aspirin therapy using the accumetrics Ultegra RPFA-ASA system. Point of Care (3), 77-82 (2004).
93. Golanski J, Chizynski K, Golanski R, Watala C: [Use of platelet function analyzer PFA-100 and whole blood aggregometry to monitor blood platelet sensitivity to acetylsalicylic acid (aspirin). Is it possible to reliably monitor antiplatelet treatment using routine laboratory diagnostic methods?]. Pol. Arch. Med. Wewn. 104(1), 355-361 (2000).
94. Homoncik M, Jilma B, Hergovich N, Stohlawetz F, Panzer S, Speiser W: Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA- 100. Thromb. Haemost. 83(2), 316-321 (2000).
95. Sambola A, Heras M, Escolar G et al.: The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets 15(7), 439-446 (2004).
96. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am. J Cardiol. 97(1), 38-43 (2006).
97. Coakley M, Self R, Marchant W, Mackie I, Malett SV, Mythen M: Use of the Platelet Function Analyser (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease. Anaesthesia 60(12), 1173-1178 (2005).
98. Macchi L, Christiaens L, Brabant S et al.: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res. 107(1-2), 45-49 (2002).
99. Andersen K, Hurlen M, Arnesen H, Seljeflot I: Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 108(1), 37-42 (2002).
100. Abaci A, Caliskan M, Bayram F et al.: A new definition of aspirin non-responsiveness by Platelet Function Analyzer-100 and its predictors. Platelets 17(1), 7-13 (2006).
101. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J: Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35(1). 175-178 (2004).
102. Roller RE, Dorr A, Ulrich S, Pilger E: Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. J. Thromb. Haemost. 13(4), 277-281 (2002).
103. Gianetti J, Parri MS, Sbrana S et al.: Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb. Res. 118(4), 487-493 (2005).
104. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK: Platelet Function Analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. J. Thromb. Haemost. 4(6), 1432 (2006).
105. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A: Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 34(4), 849-854 (2003).
106. Raman S, Jilma B: Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J. Thromb. Haemost. 2(12), 2278-2279 (2004).
107. Vander Planken MG, Claeys MJ, Vertessen FJ et al.: Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb. Res. 111(3), 159-164 (2003).
108. Hezard N, Metz D, Nazeyrollas P et al.: Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb. Haemost. 83(4), 540-544 (2000).
109. Madan M, Berkowitz SD, Christie DJ et al.: Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am. Heart J. 141(2), 226-233 (2001).
110. Coller BS, Lang D, Scudder LE: Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 95, 860-867 (1997).
111. Smith JW, Steinhubl SR, Lincoff AM et al.: Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 99(5), 620-625 (1999).
112. Kereiakes DJ, Mueller M, Howard W et al.: Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb. Thrombolysis 7(3), 265-276 (1999).
113. Wheeler GL, Braden GA, Steinhubt SR et al.: The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J. 143(4), 602-611 (2002).
114. 12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb. Res. 119(3), 277-284 (2006).
115. von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schomig A, Kastrati A: Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb. Haemost. 95(5), 910-911 (2006).
116. Wang JC, Aucoin-Barry D, Manuelian D et al.: Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am. J. Cardiol. 92(12), 1492-1494 (2003).
117. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. 43(6), 1122-1126 (2004).
118. Lev EI, Patel RT Maresh KJ et al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J. Am. Coll. Cardiol. 47(1), 27-33 (2006).
119. 12-assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective PCI. J. Thromb. Haemost. 4(11), 2516-2518 (2006).
120. Neumann FJ, Hochholzen W, Pogatsa-Murray G, Schomig; A, Gawaz M: Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 37(5), 1323-1328 (2001).
121. Harder S, Klinkhardt U, Graff J et al.: In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests. Tromb. Res. 102(1), 39-48 (2001).
122. Matzdorff AC, Kuhnel G, Kemkes-Matthes B, Voss R: Comparison of GP IIB/ IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. J. Thromb. Thrombolysis 12(2), 129-139 (2001).
123. Steinhubl SR, Talley JD, Braden GA et al.: Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103(21), 2572-2578 (2001).
124. Varon D, Dardik R, Shenkman B et al.: A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Tromb. Res. 85(4), 283-294 (1997).
125. Weiss HJ, Turritto VT, Baumgartner HR: Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. Shear rate dependent decrease of adhesion in von Willebrand's disease and Bernard-Soulier Syndrome. J. Lab. Clin. Med. 92, 750-764 (1978).
126. Ikeda Y, Handa M, Kawano K et al.: The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J. Clin. Invest 87, 1234-1240 (1991).
127. Savion N, Varon D: Impact - the cone and plate(let) analyzer: testing platelet function and anti-platelet drug response. Pathophysiol. Haemost. Thromb. 35(1-2), 83-88 (2006).
128. Shenkman B, Savion N, Dardik R, Tamarin I, Varon D: Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb. Res. 99(4), 353-361 (2000).
129. Varon D, Lashevski I, Brenner B et al.: Cone and plate(let) analyzer: monitoring glycoproteln IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am. Heart J. 135(5 Pt 2 Su), S187-S193 (1998).
130. Shenkman B, Schneiderman I Tamarin I, Kotev-Emeth S, Savion N, Varon D: Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods. Thromb. Res. 102(4), 311-317 (2001).
131. Osende JI, Fuster V, Lev EI et al.: Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 103(11), 1488-1491 (2001).
132. Hartert H: Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klin. Worbenschr. 26, 577-583 (1948).
133. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E: Evaluation of the proille of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J. Thromb. Haemost. 3(9), 2039-2043 (2005).
134. Caprini JA, Traverso CI, Arcelus II: Perspectives on thromboelastography. Semin. Thromb. Hemost. 21 (Suppl. 4), 91-93 (1995).
135. Spiess BD: Thrombelastography and cardiopulmonary bypass. Semin. Thromb. Hemost. 21(Suppl. 4), 27-33 (1995).
136. Kang Y: Thrombetastography in liver transplantation. Semin. Thromb. Hemost. 21(Suppl. 4), 34-44 (1995).
137. Gillies BSA: Thrombelastography and liver transplantation. Semin. Thromb. Hemost. 21(Suppl. 4), 45-49 (1995).
138. McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E: Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth. Analg. 100(6), 1576-1583 (2005).
139. Tantry US, Bliden KP, Gurbel PA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am. Coll. Cardiol. 46(9), 1705-1709 (2005).
140. Gurbel PA, Bliden KP Guyer K, Aggarwal N, Tantry US: Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb. Res. 119(5), 563-570 (2006).
141. Khurana S, Mattson JC, Westley S, O'Neill WW, Timmis GC, Safian RD: Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J. Lab. Clin. Med. 130(4), 401-411 (1997).
142. Jernberg T, Payne CD, Winters KJ et al.: Prasugrel achieves greater inhibition qf platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27(10), 1166-1173 (2006).
143. 12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111 (25), 3366-3373 (2005).